Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of ESG406 in Subjects With Locally Advanced/Metastatic Solid Tumors

NCT06979674 is registered in ClinicalTrials.gov with Shanghai Escugen Biotechnology Co., Ltd as lead sponsor.

NCT NCT06979674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06979674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of ESG406 in Subjects With Locally Advanced/Metastatic Solid Tumors
Lead sponsor
Shanghai Escugen Biotechnology Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
June 4, 2025
Completion date
June 30, 2028
Enrollment
556 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced/metastatic solid tumors